Methotrexate

High-dose chemotherapy protocols for treating acute lymphoblastic leukemia, osteosarcoma, primary CNS lymphoma, and non-Hodgkin lymphoma utilize methotrexate, a folate antagonist antimetabolite also used in low-dose regimens for rheumatoid arthritis, psoriasis, and other autoimmune conditions. Laboratory testing applications include therapeutic drug monitoring during high-dose methotrexate therapy (HDMTX) in oncology settings, monitoring low-dose therapy compliance in rheumatology clinics, and clinical toxicology assessments in emergency departments evaluating methotrexate overdose or delayed clearance. UTAK’s methotrexate therapeutic drug monitoring controls are available in lyophilized serum matrix at multiple concentration levels, supporting immunoassay and LC-MS/MS methods used in oncology programs and clinical laboratories monitoring high-dose chemotherapy patients. Stock and custom QC solutions help your laboratory maintain analytical method performance for methotrexate TDM assays across oncology and rheumatology testing programs.